Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Steadfast Medishield is a prominent Indian pharmaceutical company specializing in renal care and transplant medicine. Established in 2008 and headquartered in Noida, the company focuses on addressing unmet needs in the management of Chronic Kidney Disease (CKD), dialysis, and organ transplantation. Its extensive product portfolio includes flagship brands like Nodosis (sodium bicarbonate), Vaptan (tolvaptan), and Tacstead (tacrolimus), covering indications such as metabolic acidosis, hyponatremia, and post-transplant immunosuppression. Beyond its core pharmaceutical business, Steadfast has expanded into sports nutrition through its Steadfast Nutrition division and digital health services via Steadfast Health. The company is recognized for its 'first-to-market' approach in India for several renal formulations and maintains a strong presence in the global nephrology fraternity.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Steadfast.